SG11201808154XA - Use of insulin for promoting gastric emptying - Google Patents

Use of insulin for promoting gastric emptying

Info

Publication number
SG11201808154XA
SG11201808154XA SG11201808154XA SG11201808154XA SG11201808154XA SG 11201808154X A SG11201808154X A SG 11201808154XA SG 11201808154X A SG11201808154X A SG 11201808154XA SG 11201808154X A SG11201808154X A SG 11201808154XA SG 11201808154X A SG11201808154X A SG 11201808154XA
Authority
SG
Singapore
Prior art keywords
international
gastric emptying
insulin
pct
promoting gastric
Prior art date
Application number
SG11201808154XA
Other languages
English (en)
Inventor
Tal Atarot
Michal Olshansky
Original Assignee
Nutrinia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrinia Ltd filed Critical Nutrinia Ltd
Publication of SG11201808154XA publication Critical patent/SG11201808154XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SG11201808154XA 2016-03-24 2017-03-24 Use of insulin for promoting gastric emptying SG11201808154XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662312473P 2016-03-24 2016-03-24
PCT/US2017/024053 WO2017165789A1 (en) 2016-03-24 2017-03-24 Use of insulin for promoting gastric emptying

Publications (1)

Publication Number Publication Date
SG11201808154XA true SG11201808154XA (en) 2018-10-30

Family

ID=59900798

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808154XA SG11201808154XA (en) 2016-03-24 2017-03-24 Use of insulin for promoting gastric emptying

Country Status (19)

Country Link
US (1) US10046032B2 (ru)
EP (1) EP3432861B1 (ru)
JP (1) JP7102347B2 (ru)
KR (1) KR20180123114A (ru)
CN (1) CN109152733A (ru)
AR (1) AR108753A1 (ru)
AU (1) AU2017237164A1 (ru)
BR (1) BR112018069444A2 (ru)
CA (1) CA3018215C (ru)
ES (1) ES2957891T3 (ru)
HR (1) HRP20230972T1 (ru)
HU (1) HUE062950T2 (ru)
IL (1) IL261898A (ru)
MX (1) MX2018011512A (ru)
PL (1) PL3432861T3 (ru)
RS (1) RS64623B1 (ru)
RU (1) RU2018133604A (ru)
SG (1) SG11201808154XA (ru)
WO (1) WO2017165789A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018069444A2 (pt) 2016-03-24 2019-10-08 Nutrinia Ltd método para promover esvaziamento gástrico num sujeito em necessidade do mesmo, insulina para uso na promoção do esvaziamento gástrico num sujeito em necessidade do mesmo e kit para uso na promoção do esvaziamento gástrico

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
KR950014441B1 (ko) 1986-08-28 1995-11-28 코르텍스 리미티드 동물의 장에 생물학적 활성물질을 전달하는데 유용한 미세과립형 제제
FR2606597B1 (fr) 1986-11-17 1989-01-27 Rhone Poulenc Sante Nouvelle composition pour l'alimentation des ruminants contenant une substance biologiquement active et sa preparation
US4944944A (en) 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase
US5013569A (en) 1990-05-21 1991-05-07 Century Laboratories, Inc. Infant formula
US5418010A (en) 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
DE4100920A1 (de) 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5360614A (en) 1993-04-26 1994-11-01 The Estee Corporation Method of controlling the release of carbohydrates by encapsulation and composition therefor
US5405637A (en) 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
DE69616167T2 (de) 1995-06-29 2002-06-20 Nestle Sa Verfahren zur Verkapselung eines Kernmaterials mit einem Polymer durch Hochdruckbehandlung
JPH10155428A (ja) 1996-12-04 1998-06-16 Shida Kanzume Kk 毛づや改善剤及び毛づやの改善方法、並びに健康食品
CA2284682A1 (en) 1997-03-27 1998-10-15 Bristol-Myers Squibb Company Use of docosahexanoic acid and arachidonic acid enhancing the growth of preterm infants
JPH119196A (ja) 1997-06-24 1999-01-19 Meiji Seika Kaisha Ltd キトサンによる家畜の損耗防止の方法
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
DK0942780T3 (da) 1997-09-09 2003-10-27 Lyotropic Therapeutics Inc Overtrukne partikler, fremgangsmåder til fremstilling deraf og anvendelse deraf
US6399090B1 (en) 1998-06-05 2002-06-04 Insotech Ltd. Insulin supplemented infant formula
WO1999062558A1 (en) 1998-06-05 1999-12-09 Technion Research And Development Foundation Ltd. Insulin supplemented infant formula
JP2000050793A (ja) 1998-08-07 2000-02-22 Meiji Milk Prod Co Ltd 人工乳組成物
JP2000116320A (ja) 1998-10-13 2000-04-25 Bingu Gure:Kk 乳酸菌カプセル入りヨーグルト及びその製造方法
GB2345836A (en) 1999-01-25 2000-07-26 Charleville Res Animal milk replacer
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6548043B1 (en) 1999-08-03 2003-04-15 Metabolic Solutions, Inc. Measurement of gastric emptying
EP1365806A2 (en) 2000-04-19 2003-12-03 Johns Hopkins University Use of no acttivators for treatment and prevention of gastrointestinal disorders
EP1541673B1 (en) 2000-05-25 2007-04-04 Société des Produits Nestlé S.A. Probiotics for pet food applications
DE60018586T2 (de) 2000-12-15 2006-04-06 Quest International B.V. Eine Feuchtigkeit- und Sauerstoff-stabile Zusammensetzung und Verfahren zur Herstellung
JP2002209513A (ja) 2000-12-15 2002-07-30 Bingu-Gure:Kk 栄養成分を含有する多数のカプセル入り強化牛乳
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
EP1393636A4 (en) 2001-05-14 2004-10-27 Vasily Petrovich Andreichuk BIOLOGICALLY ACTIVE FOOD ADDITIVE AND BIOLOGICALLY ACTIVE FODDER ADDITIVE FOR PREVENTING IODINE DEFICIENCY AND OPTIMIZING IODINE METABOLISM, FOOD AND FORAGE PRODUCTS CONTAINING SUCH ADDITIVES
EP1395246A1 (en) 2001-05-23 2004-03-10 Institut National de la Recherche Scientifique Biocompatible compositions as carriers or excipients for pharmaceutical and nutraceutical formulations and for food protection
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US20030175403A1 (en) 2002-03-14 2003-09-18 Gurin Michael H. Potentiated bioactive additives and method of use
US20030175382A1 (en) 2002-03-14 2003-09-18 Dally Vernetta L. Heat released encapsulated yeast
CN1656205A (zh) 2002-07-01 2005-08-17 诺和酶股份有限公司 颗粒的稳定
US6835397B2 (en) 2002-12-23 2004-12-28 Balchem Corporation Controlled release encapsulated bioactive substances
CN103583696A (zh) 2003-06-20 2014-02-19 努特里尼亚有限公司 生物活性化合物保护方法及含有其的组合物
EP1758464A4 (en) 2004-05-24 2012-10-24 Nutrinia Ltd NUTRITIONAL FOOD AND SUPPLEMENT, ITS COMPOSITION, PROCESSING AND METHOD FOR ITS USE
EP1750755A1 (en) 2004-06-02 2007-02-14 Technion Research And Development Foundation, Ltd. Methods and formulations for increasing intestinal function
GB0502795D0 (en) 2005-02-10 2005-03-16 Univ Cambridge Tech Treatment of very low birthweight (vlbw) infants
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
CA2690854C (en) 2007-06-07 2017-10-17 Nutrinia Ltd. Means and methods for enhancing weight gain in poultry
US7943733B2 (en) 2007-12-20 2011-05-17 University Of Southern California Spacers to increase the expression of recombinant fusion proteins
JP5850940B2 (ja) 2010-10-21 2016-02-03 スウェディッシュ オーファン バイオビトラム パブリーク アクチエボラグ ヒト乳児の発育速度を増大させる方法
EP2520298A1 (en) 2011-05-03 2012-11-07 Assistance Publique, Hopitaux De Paris Pharmaceutical composition comprising sulfonylureas (glibenclamide) or meglitinides for use for treating hyperglycaemia or for promoting growth of a premature infant
US20150086622A1 (en) 2012-04-18 2015-03-26 Nutrinia Ltd. Growth enhancement of infants
WO2013179290A1 (en) * 2012-05-31 2013-12-05 Nutrinia Ltd. Insulin-containing infant formula
BR112018069444A2 (pt) 2016-03-24 2019-10-08 Nutrinia Ltd método para promover esvaziamento gástrico num sujeito em necessidade do mesmo, insulina para uso na promoção do esvaziamento gástrico num sujeito em necessidade do mesmo e kit para uso na promoção do esvaziamento gástrico

Also Published As

Publication number Publication date
PL3432861T3 (pl) 2023-12-18
EP3432861B1 (en) 2023-07-12
EP3432861A1 (en) 2019-01-30
KR20180123114A (ko) 2018-11-14
RU2018133604A (ru) 2020-04-24
ES2957891T3 (es) 2024-01-29
AU2017237164A1 (en) 2018-10-11
EP3432861A4 (en) 2019-10-23
CA3018215C (en) 2023-10-03
WO2017165789A1 (en) 2017-09-28
CN109152733A (zh) 2019-01-04
MX2018011512A (es) 2019-02-07
JP2019509317A (ja) 2019-04-04
US20170319663A1 (en) 2017-11-09
HUE062950T2 (hu) 2023-12-28
IL261898A (en) 2018-10-31
BR112018069444A2 (pt) 2019-10-08
JP7102347B2 (ja) 2022-07-19
AR108753A1 (es) 2018-09-26
HRP20230972T1 (hr) 2023-12-08
RS64623B1 (sr) 2023-10-31
US10046032B2 (en) 2018-08-14
EP3432861C0 (en) 2023-07-12
CA3018215A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201408228QA (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201808650QA (en) Methods of treating ocular conditions